ClinicalTrials.gg
RecruitingNCT07948915SPARkUpdated Nov 19, 2026

Sexual Function Outcomes Following Peri-clitoral PRP

An interventional study of Platelet-Rich Plasma (PRP) Injections in Sexual Function, sponsored by Medstar Health Research Institute. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Medstar Health Research Institute · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 128 studies in Sexual Dysfunction, Physiological with a site in United States — 17 open to participants now, 18 under way, none of them phase 3. Sexual Dysfunction, Physiological · United States.

Planned enrollment
57th of 108
58 · median 60
Started
2026
with 4 others
No phase
62 of 128
13 open now
Primary completion
2027-11
later than 9 of 17 live
Registered
128th of 128
by date

Among the 128 studies in Sexual Dysfunction, Physiological with a site in United States, this one is the 57th largest by planned enrollment of the 108 interventional ones that give a count, is one of 5 that started in 2026, is one of 62 with no phase, reaches primary completion later than 9 of the 17 other live ones, and was the 128th registered.

Sexual Dysfunction, Physiological

386 studies on the registry are indexed under Sexual Dysfunction, Physiological; 73 are open to participants now.

Browse Sexual Dysfunction, Physiological studies →

Open to participants now

17 of the 128 studies in Sexual Dysfunction, Physiological with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Sexual Dysfunction, Physiological studies recruiting now, 24 (51%) set no upper age limit and 20 (43%) stop at 75 or younger; 2 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Sexual Dysfunction, Physiological with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if adding platelet-rich plasma (PRP) injections near the clitoris improves sexual function more than PRP injections in the vaginal wall alone. The study includes sexually active adults who were assigned female at birth. PRP is made from a person's own blood. It contains growth factors that may help tissue heal and renew.

The main questions it aims to answer are:

Does adding PRP near the clitoris improve sexual function 6 weeks after treatment, compared with vaginal wall PRP alone? Do any improvements last at 3 and 6 months? How painful are the injections, and what side effects do participants have?

Researchers will compare two groups. All participants will get PRP injected into the front wall of the vagina. One group will also get PRP injected near the clitoris. The other group will get a placebo (sham) injection near the clitoris: the needle goes under the skin, but nothing is injected. Participants will not know which group they are in.

Participants will:

Answer questionnaires about their health and sexual function before treatment. Come to one in-person visit, about 1 hour long. At this visit they will have blood drawn to make the PRP and receive the injections.

Rate their pain shortly after the injections. Complete 3 short online follow-up visits at 6 weeks, 3 months, and 6 months. At these visits they will answer questionnaires about sexual function and side effects.

Read the detailed description

**Background and Rationale**

Female sexual dysfunction (FSD) affects approximately 43% of women in the United States, and 23% report associated distress. Non-hormonal treatment options are limited. Platelet-rich plasma (PRP) is an autologous concentrate of platelets. On activation, platelets release growth factors, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). These factors are hypothesized to promote angiogenesis, collagen synthesis, and neural regeneration in target tissues.

The Vaginal Injection of Platelet-Rich Plasma (VIP) trial was a single-blind randomized controlled trial conducted through the MedStar Health Research Institute. Compared with saline injection, anterior vaginal wall PRP produced greater improvement in Female Sexual Function Index (FSFI) total scores at 6 weeks and 6 months. PRP recipients also had higher global impression of improvement and no serious adverse events, although PRP injection was more painful than saline.

Commercial protocols (e.g., the "O-Shot") commonly add peri-clitoral injection to vaginal wall injection. Uncontrolled data that included peri-clitoral injection reported larger FSFI gains than those seen in the VIP trial (Runels et al., 2014; n=11). However, that study did not isolate the peri-clitoral component, and it reported two cases of extreme sexual arousal. Other peri-clitoral data come from studies without adjunctive vaginal wall injection.

The clitoral complex extends well beyond the glans to include the bulbs and crura. It is densely innervated and highly vascular, which makes it a plausible target for regenerative therapy. It is also a site where adverse sensory effects are of particular concern. No randomized data exist on the incremental benefit or risk of peri-clitoral PRP added to anterior vaginal wall PRP. This trial addresses that gap.

**Study Design**

This is a single-site, single-blind (participant-blinded), randomized, sham-controlled, parallel-group superiority trial. Both arms receive anterior vaginal wall PRP, so the design isolates the effect of the peri-clitoral component. Participants are randomized 1:1 using the REDCap randomization module. Unblinded study staff perform the randomization immediately before the procedure. Injecting physicians and study staff are unblinded. Allocation is concealed from participants until study completion, except in emergencies requiring knowledge of treatment assignment.

**Intervention Details**

Participants undergo venipuncture of 40-60 mL whole blood. Samples are labeled with study ID and date and transported within 30 minutes to an on-site centrifuge at MedStar Lafayette Centre. PRP is prepared with the Arthrex Angel system using a 15-minute centrifugation, which yields approximately 2-4 mL of leukocyte-rich PRP. PRP is used within 2 hours of centrifugation and requires no storage. This follows an established institutional orthopedic protocol. Residual blood product is discarded as biohazard waste, and no specimens are banked.

All injections are performed after topical anesthesia by trained, IRB-approved physicians using a 28-32 gauge needle with a superficial technique and retrograde withdrawal:

  • **Anterior vaginal wall (both arms):** Two-thirds of the PRP volume is injected just deep to the epithelium of the distal anterior vaginal wall, approximately 3 cm from the urethral meatus.
  • **Peri-clitoral, active arm:** The remaining one-third (approximately 1 mL) is delivered as two superficial injections of approximately 0.5 mL each near the junction of the clitoris, clitoral hood, and frenulum.
  • **Peri-clitoral, sham arm:** The needle is inserted at the same sites without injecting any substance.

Participants are observed for 15 minutes after injection.

**Sample Size**

The sample size was calculated in PASS 2024 (v24.0.6) for a two-sided, two-sample t-test of the difference in baseline-to-6-week change in FSFI total score. Assumptions were α=0.05, 80% power, SD of 5.1 at each time point, and a within-subject correlation of 0.5. The target difference was 4.05 points, the distribution-based FSFI MCID. Published anchor-based estimates are similar. This requires 26 participants per arm. With 10% anticipated attrition, enrollment is 29 per arm (58 total).

**Statistical Analysis**

All tests are two-sided at α=0.05. Benjamini-Hochberg false discovery rate correction is applied to secondary analyses. Missing data are handled by complete-case analysis per outcome.

  • **Primary comparison:** A two-sample t-test of between-arm difference in change scores, reported with a 95% CI.
  • **Responder analyses:** Logistic regression adjusted for baseline FSFI.
  • **Longitudinal and subdomain analyses:** Linear mixed-effects models with treatment, time, treatment×time interaction, and baseline FSFI as fixed effects and a random participant intercept. Estimated marginal means are compared at each time point.
  • **Global impression of improvement:** Cumulative logit mixed-effects models.
  • **Procedural pain:** Summarized descriptively by arm with 95% CIs.
  • **Adverse events:** Compared using Poisson regression with robust standard errors, reported as incidence rate ratios.

**Safety Monitoring**

Safety assessment focuses on outcomes specific to the peri-clitoral site: bleeding, infection, sensory changes (numbness, hypersensitivity), and unexpected or undesired arousal. An independent safety monitor reviews all adverse event data at 50% enrollment. Any serious adverse event is reported to the MHRI IRB, and enrollment is paused pending safety monitor review.

03

Conditions studied

  • Sexual Function

Keywords

  • Platelet-Rich Plasma
  • Sexual Dysfunction
  • Clitoris
  • Vagina
  • Orgasm
  • Libido
  • Regenerative Medicine
  • Women's Health
  • Female sexual function
  • Female Sexual Function Index
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years of age or older who were assigned female at birth
  • Sexually active, with at least one episode of sexual activity (alone or with a partner) in the past month
  • English speaking
  • Able to complete study questionnaires
  • Willing to undergo blood draw and genital injection procedure

Exclusion criteria

Exclusion Criteria:

  • Pregnant, suspected pregnancy, or breastfeeding/lactating
  • Active infection
  • condition
  • History of pelvic radiation
  • History of pelvic
  • Current use of anticoagulant medication
  • Prior urogenital -rich plasma injection
  • History of female genital mutilation/cutting
  • Presence of urethrovaginal mesh (including midurethral sling)
  • Chronic or acute pelvic pain preventing pelvic examination
  • Active genital infection
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
58 participants (estimated)

Study arms

  • Sham comparator
    Anterior Vaginal Wall PRP + Periclitoral Sham

    All participants in this arm will receive active PRP injection into the anterior vaginal wall; they will receive a sham injection into the peri-clitoral sites.

    Biological: Platelet-Rich Plasma (PRP) Injections

  • Experimental
    Anterior Vaginal Wall PRP + Periclitoral PRP

    All participants in this arm will receive active PRP injection into the anterior vaginal wall; they will receive active PRP injection into the peri-clitoral sites.

    Biological: Platelet-Rich Plasma (PRP) Injections

Interventions

  • BiologicalPlatelet rich plasmaStudies of Platelet rich plasmaPlatelet rich plasma pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A single treatment session. 40-60 mL of autologous whole blood is processed with the Arthrex Angel system (15-minute centrifugation), yielding approximately 2-4 mL of leukocyte-rich platelet-rich plasma (PRP), which is used within 2 hours of preparation. After topical anesthesia, all participants receive two-thirds of the PRP volume injected superficially into the distal anterior vaginal wall, approximately 3 cm from the urethral meatus, using a 28-32 gauge needle. Experimental arm: The remaining PRP (approximately 1 mL) is delivered as two superficial injections of about 0.5 mL each near the junction of the clitoris, clitoral hood, and frenulum. Sham comparator arm: A needle is inserted at the same peri-clitoral sites without injecting any substance. Participants are blinded to peri-clitoral assignment.

    Also known as: PRP

06

What researchers measure

Primary outcomes

  1. Change in Female Sexual Function Index Total Score

    Change in total Female Sexual Function Index (FSFI) score from baseline to 6 weeks after treatment, compared between the peri-clitoral PRP and peri-clitoral sham arms. The FSFI is a validated 19-item self-report questionnaire assessing six domains of sexual function: desire, arousal, lubrication, orgasm, satisfaction, and pain. Total scores range from 2.0 to 36.0, and higher scores indicate better sexual function.

    Time frame: Baseline and 6 weeks after treatment

Secondary outcomes

  1. Change in Female Sexual Function Index Total Score at 3 Months

    Change in total Female Sexual Function Index (FSFI) score from baseline to 3 months after treatment, compared between arms. The FSFI is a validated 19-item self-report questionnaire. Total scores range from 2.0 to 36.0, and higher scores indicate better sexual function.

    Time frame: Baseline and 3 months after treatment

  2. Change in Female Sexual Function Index Total Score at 6 Months

    Change in total FSFI score from baseline to 6 months after treatment, compared between arms. Total scores range from 2.0 to 36.0, and higher scores indicate better sexual function.

    Time frame: Baseline and 6 months after treatment

  3. Change in Female Sexual Function Index Domain Scores

    Change from baseline in each of the six FSFI domain scores, compared between arms. The domains are desire (range 1.2-6.0), arousal (0-6.0), lubrication (0-6.0), orgasm (0-6.0), satisfaction (0.8-6.0), and pain (0-6.0). Higher scores indicate better function.

    Time frame: Baseline, 6 weeks, 3 months, and 6 months after treatment

  4. Proportion of Participants With Clinically Meaningful Improvement

    Percentage of participants in each arm whose total FSFI score increases by at least 4.05 points from baseline, the minimal clinically important difference.

    Time frame: Baseline, 6 weeks, 3 months, and 6 months after treatment

  5. Proportion of Participants Above the Sexual Dysfunction Threshold

    Percentage of participants in each arm with a total FSFI score of 26.55 or higher, the validated cutoff for distinguishing women with and without sexual dysfunction.

    Time frame: 6 weeks, 3 months, and 6 months after treatment

  6. Patient Global Impression of Improvement

    Participant rating of change in sexual function since treatment on the Patient Global Impression of Improvement (PGI-I), a single-item 7-point scale from 1 (very much better) to 7 (very much worse). Lower scores indicate greater improvement. Compared between arms.

    Time frame: 6 weeks, 3 months, and 6 months after treatment

  7. Procedural Pain

    Pain from the injection procedure, rated on a visual analog scale from 1 (least pain) to 10 (worst pain). Higher scores indicate more pain. Compared between arms.

    Time frame: Approximately 10-15 minutes after injection on the day of treatment

  8. Adverse Events

    Number and type of adverse events in each arm. These include bleeding, infection, abnormal discharge, worsening or persistent pain, numbness, hypersensitivity, undesired changes in sexual arousal or genital sensation, and serious adverse events.

    Time frame: From treatment through 6 months after treatment

07

Study locations

1 of 1 sites recruiting
  • MedStar Health at Lafayette Centre
    Washington D.C., District of Columbia 20036, United States
    Recruiting
08

References and documents

Publications

  • Sarebani Z, Chegini V, Chen H, Aali E, Mirzadeh M, Abbaspour M, Griffiths MD, Alimoradi Z. Effect of vitamin D vaginal suppository on sexual functioning among postmenopausal women: A three-arm randomized controlled clinical trial. Obstet Gynecol Sci. 2023 May;66(3):208-220. doi: 10.5468/ogs.22038. Epub 2023 Feb 24. PubMed 36825329 ↗
  • Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008 Nov;112(5):970-8. doi: 10.1097/AOG.0b013e3181898cdb. PubMed 18978095 ↗
  • Runels C, Melnick H, Debourbon E, Roy L. A Pilot Study of the Effect of Localized Injections of Autologous Platelet Rich Plasma (PRP) for the Treatment of Female Sexual Dysfunction. J Womens Health Care. 2014;3(4):169. doi:10.4172/2167-0420.1000169
  • O'Connell HE, Sanjeevan KV, Hutson JM. Anatomy of the clitoris. J Urol. 2005 Oct;174(4 Pt 1):1189-95. doi: 10.1097/01.ju.0000173639.38898.cd. PubMed 16145367 ↗
  • Krychman M, Rowan CG, Allan BB, DeRogatis L, Durbin S, Yacoubian A, Wilkerson D. Effect of Single-Treatment, Surface-Cooled Radiofrequency Therapy on Vaginal Laxity and Female Sexual Function: The VIVEVE I Randomized Controlled Trial. J Sex Med. 2017 Feb;14(2):215-225. doi: 10.1016/j.jsxm.2016.11.322. PubMed 28161079 ↗
  • Clarke B, Gaddam N, Garcia B, Iglesia CB, Podolsky R, Dieter AA. Vaginal Injection of Platelet-Rich Plasma for Sexual Function: A Randomized Controlled Trial. Obstet Gynecol. 2026 May 1;147(5):627-635. doi: 10.1097/AOG.0000000000006256. Epub 2026 Mar 19. PubMed 41855531 ↗
  • Aglamis SO. Platelet-Derived Exosome Vulvar Injections for Sexual Dysfunction: A Retrospective Review. Aesthet Surg J. 2025 Aug 18;45(9):922-927. doi: 10.1093/asj/sjaf104. PubMed 40464751 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared. Data include sensitive sexual health and demographic information from a small, single-site sample, which poses a meaningful risk of re-identification, and participants were not consented for data sharing beyond the study team.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 100 non-industry interventional studies with no phase under Sexual Dysfunction, Physiological, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's planned 12 months is below that.

Counting every sponsor, half of 112 studies reached it within 20 months; a quarter within 10 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 19, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Nov 1, 2027
CompletionEst.
May 1, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948915
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Margot G DaBreo, MD, MPH
Contact
margot.dabreo@medstar.net
540-325-4494
Tranessa Hanson
Contact
tranessa.l.hanson@medstar.net
202-877-7854
Alexis Dieter, MD
principal investigator · Medstar Health Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Start the discussion